Cancer Articles
Results of a trial of GSK’s experimental cancer drug Blenrep showed that the drug used in combination with other treatments reduced the risk of death by 42 percent in multiple myeloma, at or after first relapse, compared to an existing treatment.
An mRNA vaccine has entered human trials as a treatment for lung cancer. Unlike traditional cancer vaccines such as the HPV vaccine, BNT116 is a therapeutic cancer vaccine designed to reduce tumor growth in patients with cancer or prevent its recurrence.
An investigational, individualized neoantigen therapy, with personalized encoded mRNA, has demonstrated potential to enable patients’ immune systems to target cells that cause cancer.
The U.S. Food and Drug Administration has approved a blood test to screen for colorectal cancer in individuals aged 45 and older with an “average risk” of colon cancer.
The U.S. Food and Drug Administration has approved Bristol Myers Squibb’s repotrectinib (Augtryo) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Researchers have discovered a rare type of immune cell that may predict how likely some patients with skin cancer will respond to immunotherapy treatment.
Researchers at City of Hope have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer.
A new cancer vaccine designed to detect and fight cancer cells without traditional cancer treatment is entering Phase III clinical trials.
Imperial College Healthcare NHS Trust has enrolled the first United Kingdom (UK) patients who have received an experimental messenger RNA (mRNA) therapy — a type of immunotherapy treatment called mRNA-4359 — in its Phase I/II clinical trial.
FDA approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with unresectable melanoma or metastatic melanoma that previously has been treated with other therapies.
An international early-phase clinical trial has found a "two-for-one" cancer immunotherapy, tebotelimab, is potentially more effective and at least as safe as standard immunotherapies.
Scientists at the University of California, Davis have identified a protein on the CD95 receptor that can “program” cancer cells to die.